Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 11/20 | 0.50 |
| ▸ | PPARA | Q07869 | 10/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.38 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.37 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29459594 | 0.90 | PPARD (0.58) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL2869616 | 0.90 | PPARD (0.58) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL13513779 | 0.83 | PPARD (0.56) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL13513783 | 0.81 | PPARD (0.61) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL2867738 | 0.81 | PPARD (0.62) | PPARDPPARAPPARGPDE5A | |
| SCHEMBL2867717 | 0.79 | PPARD (0.61) | PPARDPPARAPPARG | |
| SCHEMBL2874509 | 0.79 | IDH1 (0.50) | PPARDPPARAIDH1PPARGFFAR1 | |
| SCHEMBL13513792 | 0.78 | PPARD (0.75) | PPARDPPARAPPARG | |
| SCHEMBL14526047 | 0.77 | PPARD (0.51) | PPARDPPARAESR1FFAR1 | |
| SCHEMBL2869618 | 0.74 | PPARA (0.46) | PPARDPPARAIDH1PPARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435946-B1 | LINKED BIARYL COMPOUNDS | AMGEN INC (US) | 2013-11-06 | — | — | EP | disclosed |
| US-7645779-B2 | Linked biaryl compounds | AMGEN INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645779-B2 | Linked biaryl compounds | AMGEN INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645779-B2 | Linked biaryl compounds | AMGEN INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080161351-A1 | Linked biaryl compounds | TULARIK INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161351-A1 | Linked biaryl compounds | TULARIK INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161351-A1 | Linked biaryl compounds | TULARIK INC. | 2008-07-03 | — | — | US | disclosed |
| EP-1435946-A4 | LINKED BIARYL COMPOUNDS | TULARIK INC (US) | 2006-02-01 | — | — | EP | disclosed |
| US-6869975-B2 | Linked biaryl compounds | TULARIK INC. (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1435946-A2 | LINKED BIARYL COMPOUNDS | Tularik Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030149108-A1 | Linked biaryl compounds | TULARIK INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003024395-A2 | LINKED BIARYL COMPOUNDS | TULARIK INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149108-A1 | Linked biaryl compounds | SREBF2, SREBF1, ACACB | PPARD 55/4885PPARA 89/4885ESR1 1723/4885 |
| US-20080161351-A1 | Linked biaryl compounds | SREBF2, SREBF1, ACACB | PPARD 55/4885PPARA 89/4885ESR1 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.